Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Tyrosine kinase inhibitor therapy"'
Current Practice in the Diagnosis and Treatment of Localized Gastric Gastrointestinal Stromal Tumors
Publikováno v:
International Journal of Translational Medicine, Vol 4, Iss 3, Pp 387-401 (2024)
Gastric gastrointestinal stromal tumors (GIST) are rare, neuroectodermal tumors primarily residing in the stomach with characteristic genetic mutations. They are often identified using ultrasound and cross-sectional imaging, or they are noted during
Externí odkaz:
https://doaj.org/article/2a4c852778e944ffb2bd292fbfc6f159
Autor:
Sai-Hong Ignatius Ou, MD, Huamao M. Lin, PhD, MBA, Jin-Liern Hong, PhD, Yu Yin, MS, MPH, Shu Jin, MS, Jianchang Lin, PhD, Minal Mehta, MBBS, Danny Nguyen, MD, Joel W. Neal, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100558- (2023)
Introduction: This study describes treatment patterns and outcomes in patients with NSCLC with EGFR exon 20 insertions (EGFRex20ins) in the United States. Methods: The Flatiron Health electronic health record database was used to select three cohorts
Externí odkaz:
https://doaj.org/article/a85d4cc4ba7e4e79b72ec1af541ad695
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Huamao M. Lin, PhD, Yu Yin, MS, Victoria Crossland, PhD, Yanyu Wu, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 3, Pp 100285- (2022)
Introduction: EGFR exon 20 insertions (EGFRex20ins) are a diverse set of mutations in NSCLC that are refractory to tyrosine kinase inhibitors. We describe real-world EGFRex20ins detection patterns in patients with advanced NSCLC in the United States.
Externí odkaz:
https://doaj.org/article/55f84f50022d40019af784b3b2a2c0c7
Autor:
Tim Brandenburg, Vera Tiedje, Philipp Muchalla, Sarah Theurer, Frank Weber, Kurt Werner Schmid, Henning Dralle, Dagmar Führer
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
BackgroundThe tyrosine kinase inhibitors (TKI) vandetanib and cabozantinib are approved as targeted therapies in advanced medullary thyroid carcinoma (MTC) with symptoms or high tumour burden. Only recently, toxicity in long-time TKI usage was analys
Externí odkaz:
https://doaj.org/article/5ffa3f1563524d0ea7a90af0dab565d7
Autor:
Anurag Mehta, Smreti Vasudevan
Publikováno v:
Cancer Treatment and Research Communications, Vol 28, Iss , Pp 100398- (2021)
Background: The predictive value of rare epidermal growth factor receptor gene (EGFR) mutations for non-small cell lung carcinoma (NSCLC) patients remain elusive. We evaluated the distribution, clinicopathological association, tyrosine kinase inhibit
Externí odkaz:
https://doaj.org/article/56a0105f008343629a69350596e34b85
Publikováno v:
Urology Case Reports, Vol 14, Iss C, Pp 18-20 (2017)
Paraneoplastic syndromes are commonly encountered in renal cell carcinoma, but neurological manifestations are rare. Herein we report a case of a patient with locally advanced renal cell carcinoma who presented with Parkinson-like symptoms which proh
Externí odkaz:
https://doaj.org/article/831e479e9b4a467397a3fc3983ace9c0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Satoshi Oizumi, Kentaro Tanaka, Toshiaki Kikuchi, Masahiro Seike, Makoto Maemondo, Hajime Asahina, Kunihiko Kobayashi, Hiroshi Kagamu, Isamu Okamoto, Kenji Sugio, Takeshi Isobe, Satoshi Morita, Kazuhisa Takahashi
Publikováno v:
Clinical Lung Cancer. 22:147-151
Background Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is now a standard treatment of previously untreated EGFR-mutated advanced non–small-cell lung cancer (NSCLC). However, disease progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc37c91617ce60b023ff54daf24ccaf2
https://doi.org/10.1016/j.cllc.2020.09.023
https://doi.org/10.1016/j.cllc.2020.09.023
Autor:
Hao-Yu Lin, Jau-Song Yu, Chia-Jung Yu, Ko-Jiunn Liu, Ting-Feng Hsiao, Hsiang-Pu Feng, Gee-Chen Chang, Yi-Cheng Wu, Yen-Chuan Chiu, Kun-Yi Chien, Chih-Liang Wang
Publikováno v:
Clinical Cancer Research. 26:3220-3229
Purpose: EGFR tyrosine kinase inhibitors (EGFR-TKI) benefit patients with advanced lung adenocarcinoma (ADC) harboring activating EGFR mutations. We aimed to identify biomarkers to monitor and predict the progression of patients receiving EGFR-TKIs v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f7fbeb6022e2661884a96e46569c1f5
https://doi.org/10.1158/1078-0432.ccr-19-3972
https://doi.org/10.1158/1078-0432.ccr-19-3972